Research map: Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial

Back to the article

Papers in this map

  1. Clinical End Points in Coronary Stent Trials · Donald E. Cutlip · 2007 · 5526 citations · Cited by this paper
  2. Effects of inhaled nitric oxide on the pulmonary circulatory system in a porcine model of heart transplantation · 2026 · Related
  3. Standardized Bleeding Definitions for Cardiovascular Clinical Trials · Roxana Mehran · 2011 · 4533 citations · Cited by this paper
  4. Trends in the clinical profile, management and prognosis of type A aortic syndrome over the last 25 years · 2026 · Related
  5. Third Universal Definition of Myocardial Infarction · Kristian A. Thygesen · 2012 · 3003 citations · Cited by this paper
  6. Prognostic value of combined serial changes in VExUS score and lung ultrasound in acute decompensated heart failure · 2026 · Related
  7. Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden · Bo Lagerqvist · 2007 · 1197 citations · Cited by this paper
  8. Cold exposure, sunlight, and particulate matter in acute heart failure: signals and uncertainties · 2026 · Related
  9. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials · Francesco Costa · 2017 · 1190 citations · Cited by this paper
  10. Long-term outcomes of primary invasive versus initial conservative treatment in elderly patients with acute myocardial infarction · 2026 · Related
  11. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk · Philip M. Urban · 2015 · 816 citations · Cited by this paper
  12. From arterial pressure to tissue perfusion: blood-pressure targets after resuscitated infarction-related cardiac arrest · 2026 · Related
  13. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk · Philip M. Urban · 2019 · 621 citations · Cited by this paper
  14. Catecholamines in cardiogenic shock - dosis fecit venenum · 2026 · Related
  15. Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk · Marco Valgimigli · 2021 · 590 citations · Cited by this paper
  16. Cardiopulmonary interactions during positive pressure ventilation: a clinico-physiological framework · 2026 · Related
  17. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial · Jürgen Pache · 2003 · 560 citations · Cited by this paper
  18. Acute heart failure diagnosis and vasodilator use in a nationwide registry study · 2026 · Related
  19. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines · Sunil V. Rao · 2025 · 410 citations · Cited by this paper
  20. Change in remnant lipid-inflammatory index predicts long-term outcomes in AMI survivors with achieved LDL-C targets · 2026 · Related
  21. Role of Endothelial Shear Stress in Stent Restenosis and Thrombosis · Konstantinos C. Koskinas · 2012 · 350 citations · Cited by this paper
  22. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk · Stephan Windecker · 2020 · 290 citations · Cited by this paper
  23. Stent Thrombosis Redux — The FDA Perspective · Andrew A. Farb · 2007 · 284 citations · Cited by this paper
  24. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial · David E. Kandzari · 2017 · 277 citations · Cited by this paper
  25. Coronary balloon angioplasty, stents, and scaffolds · Robert A. Byrne · 2017 · 275 citations · Cited by this paper
  26. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial · Thomas Pilgrim · 2014 · 269 citations · Cited by this paper
  27. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials · Raffaele Piccolo · 2019 · 236 citations · Cited by this paper
  28. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial · Juan F. Iglesias · 2019 · 191 citations · Cited by this paper
  29. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial · Clemens von Birgelen · 2018 · 146 citations · Cited by this paper
  30. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis · Dániel Aradi · 2012 · 141 citations · Cited by this paper
  31. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials · Francesco Costa · 2022 · 138 citations · Cited by this paper
  32. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) · Marco Valgimigli · 2013 · 109 citations · Cited by this paper
  33. Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View · Atsushi Sakamoto · 2018 · 109 citations · Cited by this paper
  34. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials · Marco Valgimigli · 2024 · 108 citations · Cited by this paper
  35. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation · Roxana Mehran · 2021 · 103 citations · Cited by this paper
  36. Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention · Felice Gragnano · 2024 · 91 citations · Cited by this paper
  37. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI · Marco Valgimigli · 2021 · 79 citations · Cited by this paper
  38. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent · Julie Doostzadeh · 2009 · 70 citations · Cited by this paper
  39. P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis · Mattía Galli · 2024 · 62 citations · Cited by this paper

Source: OpenAlex (CC0)